Hikma Pharmaceuticals (GB:HIK) has released an update.
Hikma Pharmaceuticals PLC has announced a significant share award under its 2023 Long Term Incentive Plan to key executive Hafrun Fridriksdottir. The award, which involves no initial cost to the recipient, will vest based on continued employment and performance conditions over a three-year period with an additional two-year holding period. The grant, consisting of 57,374 ordinary shares, underscores the company’s commitment to aligning the interests of its management with those of its shareholders.
For further insights into GB:HIK stock, check out TipRanks’ Stock Analysis page.
